- 1 HR134
- 2 217851-2
- 3 By Representative Mooney
- 4 RFD: Rules
- 5 First Read: 08-MAR-22

1	217851-2:n:03/08/2022:FC/ma LSA2022-730R1
2	
3	
4	
5	
6	
7	
8	DECLARING THE MONTH OF MARCH 2022 AS TRIPLE NEGATIVE
9	BREAST CANCER AWARENESS MONTH.
10	
11	WHEREAS, breast cancer is among the most commonly
12	diagnosed cancer and is the second leading cause of cancer
13	death among women in the United States; and
14	WHEREAS, approximately 281,550 women will be
15	diagnosed with breast cancer, and nearly 43,600 will die with
16	this malignancy in 2022; and
17	WHEREAS, Triple Negative Breast Cancer is one of
18	many forms of breast cancer and accounts for about 15-30
19	percent of all diagnosed invasive breast cancer cases in the
20	United States; and
21	WHEREAS, of the new breast cancer cases diagnosed in
22	2019 in the United States, more than 53,700 were Triple
23	Negative Breast Cancer with highest prevalence among younger
24	women, Black and Hispanic women, women with type 2 diabetes or
25	carrying excess weight in the abdomen area, and those with
26	BRCA1 mutations; and

1 WHEREAS, due to its aggressive behavior, Triple
2 Negative Breast Cancer grows quickly, is more likely to have
3 spread at the time it is found, and is more likely to come
4 back after treatment than other types of breast cancer; and
5 WHEREAS, people diagnosed with metastatic Triple

WHEREAS, people diagnosed with metastatic Triple
Negative Breast Cancer have a less than 30 percent chance of
surviving more than five years; and

WHEREAS, Triple Negative Breast Cancer cells do not contain and are considered negative for the three key receptors that medicines typically target in other types of breast cancers; therefore, there are limited treatment options that can be used to treat the cancer; and

WHEREAS, patients with an early diagnosis can often be treated with chemotherapy, radiation, and surgery; however, the limited therapies available specifically addressing the management of Triple Negative Breast Cancer has made treating this disease a challenge for clinicians; and

WHEREAS, recent innovation in targeted therapies has fueled advances in the fight against Triple Negative Breast Cancer; and

WHEREAS, studies have shown that Triple Negative
Breast Cancer disease-specific mortality rates are often
higher if patients have Medicaid or Medicare or are lower
socio-economic status, and compared with non-Hispanic women,
Black women are 48 percent less likely to receive guideline
adherent care and have an approximate two-fold higher

mortality incidence, resulting in a disproportionately higher risk of death from Triple Negative Breast Cancer; and

WHEREAS, advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of Triple Negative Breast Cancer on racial and minority communities raises considerations of the underlying determinants driving the disparities; and

WHEREAS, it is necessary to promote Triple Negative Breast Cancer education to raise awareness about the disease-related disparities and to tackle inequities within the health care delivery, such as inadequate access to screening, diagnostic testing, and care, and to improve early detection and survival; now therefore,

BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF
THE LEGISLATURE OF ALABAMA, That we declare the month of March
2022 as Triple Negative Breast Cancer Awareness Month in the
State of Alabama.